05/17/2019
"A month’s supply of Truvada costs roughly $6 to make and sells for more than $1,600 in the United States, according to the PrEP4All Collaboration, an advocacy group. (PrEP stands for pre-exposure prophylaxis, a strategy to prevent H.I.V. infection.) Owing partly to those prices, only about 18 percent of the million or so at-risk Americans who need the drug have access to it."
"The much bigger tragedy lurking in this news: No matter how Gilead’s donation turns out, a majority of patients who would benefit from Truvada — and whose tax dollars helped pay for its development — still won’t be able to get the drug."
A donation of H.I.V.-prevention drugs from the pharmaceutical giant Gilead could benefit shareholders more than patients.